Early worsening of diabetic retinopathy due to intensive glycaemic control

Clin Exp Ophthalmol. 2019 Mar;47(2):265-273. doi: 10.1111/ceo.13393. Epub 2018 Nov 19.

Abstract

The prevalence of diabetes and diabetic retinopathy is increasing around the world. Glycaemic control is important in reducing the long-term risk of complications of diabetes, however intensive glycaemic control, particularly in patients with longstanding and poorly controlled diabetes, is associated with the risk of early worsening of diabetic retinopathy and vision loss. We present two clinical cases to illustrate the presentation of early worsening and to highlight a role for intravitreal anti-vascular endothelial growth factor therapies in ameliorating this phenomenon, as well as a review of the current understanding of this phenomenon. We emphasise the importance of identifying individuals at risk of early worsening of diabetic retinopathy and recommend regular ophthalmological review during the period of intensive glycaemic control to ensure optimal visual outcomes.

Keywords: anti-vascular endothelial growth factor; diabetic retinopathy; early worsening phenomenon; glycaemic control.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use
  • Bevacizumab / therapeutic use
  • Blood Glucose / metabolism
  • Diabetes Mellitus, Type 2 / physiopathology
  • Diabetic Retinopathy / diagnosis
  • Diabetic Retinopathy / drug therapy
  • Diabetic Retinopathy / physiopathology*
  • Fluorescein Angiography
  • Glycated Hemoglobin / metabolism
  • Glycemic Index / physiology*
  • Humans
  • Intravitreal Injections
  • Male
  • Middle Aged
  • Tomography, Optical Coherence
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Visual Acuity / physiology

Substances

  • Angiogenesis Inhibitors
  • Blood Glucose
  • Glycated Hemoglobin A
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • hemoglobin A1c protein, human
  • Bevacizumab